10-Q/APeriod: Q2 FY2002

THERMO FISHER SCIENTIFIC INC. Quarterly Report (Amendment) for Q2 Ended Jun 29, 2002

Filed August 14, 2002For Securities:TMO

Summary

Thermo Fisher Scientific Inc. (TMO) reported its financial results for the fiscal quarter ending June 29, 2002. The company saw a decrease in revenue for the second quarter, reporting $509.1 million compared to $542.5 million in the same period last year. However, operating income significantly improved to $35.2 million from $14.2 million in the prior year's quarter, driven by cost reductions and the cessation of goodwill amortization following the adoption of SFAS No. 142. Profitability was impacted by various restructuring and unusual charges in both periods. The company continues to navigate a challenging market, particularly in its Optical Technologies and Measurement and Control segments, due to slowdowns in the semiconductor, telecommunications, energy, and steel industries. Despite revenue headwinds, the company demonstrated improved operational efficiency and a strong focus on cost management. Significant cash was used in financing activities, primarily for debt redemption and securities repurchase, while investing activities saw proceeds from asset sales and continued acquisitions.

Key Highlights

  • 1Total revenues for the second quarter of 2002 decreased to $509.1 million from $542.5 million in Q2 2001, an approximate 6% decline.
  • 2Operating income saw a substantial improvement, rising to $35.2 million in Q2 2002 from $14.2 million in Q2 2001.
  • 3Net income for the second quarter of 2002 was $68.5 million ($0.38 per diluted share), a significant increase from $25.0 million ($0.14 per diluted share) in Q2 2001.
  • 4The company adopted SFAS No. 142, ceasing goodwill amortization, which positively impacted reported income.
  • 5Restructuring and unusual costs continued to impact results, with $17.0 million recorded in Q2 2002 compared to $33.6 million in Q2 2001.
  • 6The Life and Laboratory Sciences segment showed revenue growth of $4.3 million, while Measurement and Control and Optical Technologies segments experienced revenue declines.
  • 7Cash used in financing activities was significant, totaling $306.4 million in the first six months of 2002, largely due to debt redemptions and stock repurchases.

Frequently Asked Questions

The company experienced a revenue decline in the second quarter of 2002 compared to the prior year, indicating challenging market conditions, particularly in the Optical Technologies and Measurement and Control segments. However, operating income and net income showed significant improvement due to cost-saving measures, restructuring benefits, and the adoption of new accounting standards (SFAS No. 142) that eliminated goodwill amortization.

The decrease in revenue is primarily attributed to slowdowns in key customer industries, including semiconductor, telecommunications, energy, and steel. Divestitures of certain businesses also contributed to the revenue decline in specific segments like Measurement and Control.

Thermo Fisher Scientific implemented cost reduction and productivity measures. The cessation of goodwill amortization due to SFAS No. 142 also significantly reduced reported expenses. The company also incurred substantial restructuring charges to streamline operations and reduce costs.

Consolidated working capital remained stable. Operating activities used cash in the first six months of 2002, partly due to discontinued operations and restructuring actions. The company used significant cash for financing activities, including debt redemption and share repurchases. Management believes existing resources and expected cash flow are sufficient for future working capital requirements.